X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3694) 3694
Publication (502) 502
Book Review (46) 46
Book Chapter (11) 11
Magazine Article (11) 11
Newsletter (11) 11
Newspaper Article (5) 5
Conference Proceeding (4) 4
Transcript (4) 4
Data Set (1) 1
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3277) 3277
hiv infections - drug therapy (2578) 2578
male (1924) 1924
ritonavir - therapeutic use (1869) 1869
female (1762) 1762
adult (1616) 1616
index medicus (1575) 1575
ritonavir (1574) 1574
hiv protease inhibitors - therapeutic use (1513) 1513
infectious diseases (1480) 1480
anti-hiv agents - therapeutic use (1302) 1302
middle aged (1151) 1151
drug therapy, combination (1118) 1118
pharmacology & pharmacy (1072) 1072
hiv (1048) 1048
immunology (836) 836
hiv infections - virology (831) 831
protease inhibitors (820) 820
antiretroviral therapy (750) 750
lopinavir (747) 747
viral load (742) 742
treatment outcome (711) 711
ritonavir - administration & dosage (671) 671
virology (629) 629
hiv-1 - drug effects (627) 627
ritonavir - adverse effects (591) 591
cd4 lymphocyte count (565) 565
hiv protease inhibitors - adverse effects (533) 533
pharmacokinetics (531) 531
drug interactions (512) 512
drug therapy (508) 508
microbiology (505) 505
antiviral agents (492) 492
hiv infection (480) 480
hiv protease inhibitors - administration & dosage (470) 470
reverse transcriptase inhibitors - therapeutic use (444) 444
therapy (443) 443
pyrimidinones - therapeutic use (427) 427
antiretroviral therapy, highly active (425) 425
anti-hiv agents - administration & dosage (417) 417
aids (402) 402
anti-hiv agents - adverse effects (400) 400
sulfonamides - therapeutic use (384) 384
rna, viral - blood (383) 383
hiv-1 (381) 381
efficacy (379) 379
hiv-1 - genetics (360) 360
ritonavir - pharmacokinetics (357) 357
lopinavir/ritonavir (355) 355
human immunodeficiency virus--hiv (350) 350
hiv protease inhibitors - pharmacokinetics (345) 345
pyridines - therapeutic use (337) 337
hiv infections - immunology (331) 331
aged (328) 328
safety (326) 326
antiretroviral drugs (318) 318
health aspects (318) 318
hiv infections - complications (318) 318
highly active antiretroviral therapy (317) 317
darunavir (313) 313
adolescent (310) 310
research (303) 303
atazanavir sulfate (302) 302
human-immunodeficiency-virus (298) 298
hiv infections - blood (296) 296
drug administration schedule (295) 295
dosage and administration (292) 292
infection (291) 291
protease inhibitor (284) 284
saquinavir (283) 283
hiv protease inhibitors - pharmacology (281) 281
aids/hiv (279) 279
drug combinations (279) 279
tenofovir (276) 276
saquinavir - therapeutic use (274) 274
ritonavir - pharmacology (271) 271
indinavir (266) 266
young adult (260) 260
lamivudine - therapeutic use (259) 259
lopinavir - therapeutic use (258) 258
genotype (257) 257
indinavir - therapeutic use (254) 254
hiv-infected patients (252) 252
prospective studies (252) 252
retrospective studies (251) 251
anti-hiv agents - pharmacokinetics (246) 246
oligopeptides - therapeutic use (242) 242
drug resistance, viral (240) 240
care and treatment (236) 236
active antiretroviral therapy (234) 234
antiviral agents - therapeutic use (226) 226
atazanavir (224) 224
hiv-1-infected patients (224) 224
virus diseases (224) 224
child (222) 222
efavirenz (221) 221
cohort studies (217) 217
analysis (215) 215
human immunodeficiency virus (212) 212
resistance (212) 212
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3581) 3581
Spanish (84) 84
French (31) 31
German (19) 19
Japanese (7) 7
Russian (6) 6
Chinese (2) 2
Czech (2) 2
Dutch (2) 2
Hebrew (1) 1
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents
Journal Article